Organization
Institut universitaire de cardiologie et de pneumologie de Québec - IUCPQ, Quebec, QC, Canada
1 abstract
Abstract
A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy.Org: Hematology-Oncology Division, University of Montreal Health Centre (CHUM), Montréal, QC, Canada, CISSS des Laurentides, St Jerome, QC, Canada, Hopital Maisonneuve-Rosemont, Montreal, QC, Canada, Institut universitaire de cardiologie et de pneumologie de Québec - IUCPQ, Quebec, QC, Canada, Institut de recherche en immunologie et en cancérologie · IRIC, Montreal, QC, Canada,